The crucial field of early autism screening just saw a new infusion of capital. Aignosis, an AI-based company dedicated to this vital area, has announced it closed a $418K seed funding round. This initial investment provides backing for the startup as it works to bring advanced artificial intelligence solutions to a critical aspect of developmental health.
Aignosis's core mission centers on leveraging AI to facilitate earlier detection of autism. The company believes that more timely diagnosis can significantly impact intervention strategies and long-term outcomes for individuals, making its technology a key focus for improving care.











